How COVID-19 Impacts Our Service
Scharfstein Gibbings Walen Fisher LLP is committed to following the guidelines and recommendations outlined by the federal and provincial health authorities to ensure the safety and well being of employees, colleagues, clients, friends, and families. To that end, we have taken proactive and precautionary measures and will continue to adjust our operations and policies accordingly.
Below is a list of helpful links to our most current operations and policies:
- Scharfstein Gibbings Walen Fisher LLP – A Message from our Managing Partner
- Frequently Asked Questions About Our Office During COVID-19
Please contact our office if you have any further questions or concerns.
Phone: (306) 653-2838
Email: firstname.lastname@example.orgCautionary note: If you are not presently a client of Scharfstein Gibbings Walen Fisher LLP, any information you communicate in your email is not protected by lawyer/client confidentiality, nor is a lawyer/client relationship established by our receipt of this email. Before we can discuss your matter, we must ensure that we do not have a conflict of interest. Please do not send us any confidential information in your e-mail.
During these unprecedented times, our thoughts are with those who have been most impacted, as well as those striving to contain and treat it.
COVID-19 and the Legal System
The personal and business impacts of the COVID-19 pandemic are wide-ranging and continuously changing, raising significant legal challenges. Scharfstein Gibbings Walen Fisher LLP remains committed to providing our clients with the tools and support necessary to successfully navigate these turbulent circumstances:
- COVID-19 for Landlord and Property Managers
- COVID-19: Document Execution Protocol
- COVID-19: Changes to the EI Benefits Program
As the COVID-19 situation continues to evolve, we encourage you to check back on our website for more information as the news, government recommendations and announcements and recent legal decisions from across Canada continues to develop.